Saxenda (liraglutide 3.0 mg) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with comorbidities. Noticing blood in urine whilst taking Saxenda can be alarming. Whilst there is no established direct causal link between Saxenda and haematuria in current evidence, any new occurrence of blood in urine warrants prompt clinical evaluation. Haematuria may arise from numerous causes, ranging from urinary tract infections to more serious underlying pathology. This article explores potential causes, when to seek medical attention, and how to manage your health whilst taking Saxenda.

Understanding Blood in Urine While Taking Saxenda

Saxenda (liraglutide 3.0 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with weight-related comorbidities. Administered as a once-daily subcutaneous injection, Saxenda works by mimicking the action of the naturally occurring hormone GLP-1, which regulates appetite and food intake. By activating GLP-1 receptors in the brain, it enhances feelings of satiety, reduces hunger, and slows gastric emptying, thereby supporting calorie reduction and weight loss.

The presence of blood in urine (haematuria) whilst taking Saxenda can understandably cause concern. Haematuria may present as visible blood, making the urine appear pink, red, or cola-coloured (macroscopic haematuria), or it may only be detectable through laboratory testing (microscopic haematuria). According to the Saxenda Summary of Product Characteristics (SmPC), there is no established direct causal link between Saxenda and haematuria in the current evidence base.

However, any new occurrence of blood in the urine warrants clinical evaluation, regardless of concurrent medication use. Haematuria can arise from numerous causes—ranging from benign and self-limiting conditions to more serious underlying pathology. It's worth noting that dehydration from gastrointestinal side effects of Saxenda (such as nausea, vomiting or diarrhoea) could potentially affect kidney function, so maintaining adequate hydration during treatment is important.

When taking any prescription medication, including Saxenda, it is essential to report new or unusual symptoms to your GP or healthcare provider promptly. This ensures appropriate investigation and management, and helps distinguish between coincidental findings and potential medication-related effects.

Possible Causes of Haematuria During Saxenda Treatment

While Saxenda itself is not recognised as a direct cause of haematuria, several factors may contribute to blood in the urine during treatment. Understanding these potential causes is crucial for appropriate clinical assessment.

Urinary tract infections (UTIs) are among the most common causes of haematuria, particularly in women. Symptoms typically include dysuria (painful urination), increased urinary frequency, urgency, and suprapubic discomfort. UTIs require prompt assessment and appropriate antibiotic treatment according to local NHS antimicrobial guidelines.

Kidney stones (renal calculi) can cause haematuria, often accompanied by severe flank pain radiating to the groin (renal colic). Dehydration—which may occur if gastrointestinal side effects of Saxenda such as nausea or vomiting reduce fluid intake—could theoretically increase the risk of stone formation. While this is not a documented adverse effect of Saxenda, maintaining adequate hydration during treatment is advisable.

Bladder or kidney pathology, including benign conditions such as bladder inflammation (cystitis) or more serious concerns such as malignancy, must be considered, particularly in patients over 45 years or those with risk factors such as smoking history.

Menstruation in women can occasionally contaminate urine samples, leading to a false impression of haematuria. Repeat testing outside the menstrual period may be necessary.

Other medications or supplements taken concurrently with Saxenda, particularly anticoagulants or antiplatelet agents, may increase bleeding risk. However, haematuria still warrants full evaluation even in patients taking these medications and should not be attributed solely to them.

Coincidental medical conditions unrelated to Saxenda—such as glomerulonephritis, polycystic kidney disease, or prostate enlargement in men—may also present with haematuria. It is vital that healthcare professionals conduct a comprehensive assessment to identify the underlying cause rather than attributing symptoms solely to Saxenda without evidence.

When to Seek Medical Attention for Blood in Urine

Call 999 or go to A&E immediately if you have blood in your urine with:

• Severe abdominal or flank pain, which may indicate kidney stones or other acute renal pathology

• Fever, rigors, or feeling systemically unwell, suggesting possible pyelonephritis (kidney infection) or sepsis

• Inability to pass urine or significant reduction in urine output, which may indicate urinary retention or acute kidney injury

• Passing blood clots in the urine, which warrants urgent urological assessment

• Dizziness, weakness, or signs of significant blood loss, such as pallor or rapid heart rate

For less severe symptoms, contact NHS 111 or your GP surgery for advice.

Routine but prompt GP assessment (within 1–2 working days) is appropriate if you notice blood in your urine without the above alarm features. Your GP will conduct a thorough history and examination, including:

• Urinalysis and urine microscopy, culture, and sensitivity testing

• Blood tests to assess renal function (urea, creatinine, estimated glomerular filtration rate)

• Blood pressure measurement

• Review of current medications, including Saxenda

According to NICE guidance (NG12), an urgent suspected cancer referral to urology (two-week wait) is required for:

• Adults aged 45 and over with unexplained visible haematuria without urinary tract infection, or visible haematuria that persists or recurs after successful treatment of UTI

• Adults aged 60 and over with unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test

Do not stop taking Saxenda without consulting your prescriber, as abrupt discontinuation may affect your weight management plan. Your healthcare team will determine whether any medication adjustment is necessary based on investigation findings.

Managing Side Effects and Monitoring Your Health on Saxenda

Effective management of Saxenda treatment requires ongoing monitoring and proactive communication with your healthcare team. While haematuria is not a recognised side effect of Saxenda, being vigilant about your overall health during treatment is essential.

Common side effects of Saxenda include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, particularly during dose titration. These effects are usually transient and can be minimised by:

• Following the recommended gradual dose escalation schedule

• Taking Saxenda at a consistent time each day

• Eating smaller, more frequent meals

• Avoiding high-fat foods that may exacerbate nausea

• Maintaining adequate hydration, especially if experiencing vomiting or diarrhoea

Regular monitoring should include:

• Weight and BMI tracking to assess treatment efficacy

• Blood glucose monitoring if you have type 2 diabetes or prediabetes

• Renal function tests as clinically indicated, particularly if you develop dehydration

• Blood pressure measurements, as weight loss may necessitate adjustment of antihypertensive medications

• Resting heart rate, as liraglutide can increase heart rate; discuss persistent tachycardia with your clinician

Important safety warnings include:

• Stop Saxenda and seek urgent medical attention if you suspect pancreatitis (severe, persistent abdominal pain radiating to the back, sometimes with vomiting)

• Be alert to symptoms of gallbladder disease (right upper quadrant pain, particularly after meals, jaundice, fever), as rapid weight loss increases risk

• Monitor for changes in mood or thoughts of self-harm, as suicidal thoughts have been reported with Saxenda

Maintain open communication with your prescriber about all symptoms, even those that seem unrelated to Saxenda. Keep a symptom diary if helpful, noting the timing, severity, and any associated factors.

If haematuria is confirmed and investigated, your healthcare team will determine the underlying cause and appropriate management. The decision to continue, interrupt, or stop Saxenda should be made by your prescriber based on clinical findings. In some cases, temporary interruption may be necessary, particularly if you develop dehydration or acute kidney problems.

Report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).

Frequently Asked Questions